Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)

Market Cap	3.57T
Revenue (ttm)	210.92B
Net Income (ttm)	-10.92B
Shares Out	23.26M
EPS (ttm)	-474.29
PE Ratio	n/a
Forward PE	n/a
Dividend	200.00 (0.13%)
Ex-Dividend Date	Dec 27, 2024

Volume	253,994
Average Volume	296,481
Open	159,700
Previous Close	149,800
Day's Range	151,000 - 160,800
52-Week Range	88,200 - 230,000
Beta	1.55
RSI	39.73
Earnings Date	Mar 20, 2025

About Sam Chun Dang Pharm.

Sam Chun Dang Pharm. Co., Ltd engages in the manufacturing and sale of pharmaceutical products in South Korea. It provides ethical and over the counter products in various therapeutic areas comprising ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company is also involved in exporting activities. Sam Chun Dang Pharm. Co., Ltd was founded in 1943 and is headquartered in Seoul, S...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1943
• Employees: 409
• Stock Exchange: KOSDAQ
• Ticker Symbol: 000250

Financial Performance

In 2024, Sam Chun Dang Pharm.'s revenue was 210.92 billion, an increase of 9.47% compared to the previous year's 192.67 billion. Losses were -10.92 billion, 5.14% more than in 2023.